FT-005 / Hofseth Biocare - LARVOL DELTA

Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity (GlobeNewswire) - "HBC Immunology Inc...reports today the successful completion of the first in vivo study within its prostate cancer development program. The study assessed whether the combination of targeted hormonal therapy, bicalutamide, and FT-002 or FT-005 was better at suppressing PC3 tumour growth compared to control (no treatment). The FT peptides are HBCI’s two leading drug candidates, and both slowed tumour growth. By the end of the study mean tumour volumes were significantly smaller with FT-005 treatment (p<0.05) compared to control but the effect of FT-002 did not reach significance. Bicalutamide alone had a minimal impact on tumour growth."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical prostate cancer models. (ASCO 2023) - " Eight candidate FTH1-modulatory peptides (FT-001 to -008, all 7- or 8-mer peptides) were identified in the SPH peptide mix and subsequently sequenced and synthesized. Antiproliferative effects of individual FT peptides were assessed in combination with ARis (bicalutamide/BIC or enzalutamide/ENZ) in phenotypically distinct PC cell lines (LNCaP, PC3, VCaP, ENZR-VCaP) and compared to the inhibitory effect of SPH-ARi combination or ARi monotherapy... FT-002 and -005 synergistically combine with ARis to significantly attenuate PC tumor growth in vitro. Gene expression profiling implicates peptide-mediated FTH1 and TFRC modulation in the mode of action to interfere with tumor cell iron metabolism. Novel research perspectives implicate ferritin and FTH1 expression levels in prostate carcinogenesis and tumor progression."

Preclinical • Genito-urinary Cancer • Metabolic Disorders • Oncology • Prostate Cancer • Solid Tumor • FTH1

Hofseth Biocare ASA: ADVANCING THE TREATMENT OF PROSTATE CANCER WITH PUBLICATION OF FTH1 RESEARCH ABSTRACT AHEAD OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING (GlobeNewswire) - "HBC is pleased to announce the online publication of its abstract...ahead of the annual ASCO meeting in Chicago, June 2-5, 2023....In preclinical models, including those published in the ASCO abstract, FT-002 and FT-005 have shown a consistent ability to modulate iron metabolism within tumour cells to both enhance tumour cell sensitivity to standard of care hormone therapy as well as reversing resistance to standard hormone therapy."

Preclinical • Oncology • Solid Tumor